ADARB1 antibodies are widely used to investigate the protein’s expression and function in diverse biological contexts:
Lung Adenocarcinoma (LUAD): Low ADARB1 expression correlates with poor prognosis, shorter survival, and increased metastasis. Studies using ADARB1 antibodies in Western blot and RT-PCR confirmed its tumor-suppressive role in LUAD cell lines (e.g., H358, A549) .
Mechanistic Insights: Knockdown of ADARB1 via siRNA enhances LUAD cell migration, as demonstrated in wound healing assays .
ADARB1 edits the Q/R site of the GluA2 subunit of AMPA receptors, critical for regulating calcium permeability in neurons. Antibodies help validate ADARB1 expression in brain tissues and cell models .
While ADARB1’s role is less defined than ADAR1 in immune signaling, its antibodies aid in studying potential cross-talk with innate immune pathways .
Band Discrepancies: Western blot often shows a strong ~50 kDa band alongside the predicted 75 kDa band, likely due to splice variants or post-translational modifications .
Methylation Link: DNA methylation inhibitors (e.g., 5-aza-2-deoxycytidine) upregulate ADARB1, suggesting epigenetic regulation in cancer .